Georgia Colleluori1, Lina Aguirre2, Richard Dorin3, David Robbins3, Dean Blevins4, Yoann Barnouin4, Rui Chen4, Clifford Qualls5, Dennis T Villareal4, Reina Armamento-Villareal6. 1. Baylor College of Medicine, One Baylor Plaza, 77030 Houston, TX, USA; Michael E. DeBakey VA Medical Center, 2002 Holcombe Blvd, 77030 Houston, TX, USA; University Campus Biomedico of Rome, Via Alvaro del Portillo, 21 04000100, Rome, Italy. 2. New Mexico VA Health Care System, 1501 San Pedro SE, 87108 Albuquerque, NM, USA. 3. New Mexico VA Health Care System, 1501 San Pedro SE, 87108 Albuquerque, NM, USA; University of New Mexico School of Medicine, 87131 Albuquerque, NM, USA. 4. Baylor College of Medicine, One Baylor Plaza, 77030 Houston, TX, USA; Michael E. DeBakey VA Medical Center, 2002 Holcombe Blvd, 77030 Houston, TX, USA. 5. University of New Mexico School of Medicine, 87131 Albuquerque, NM, USA; Biomedical Research Institute of New Mexico, 1501 San Pedro SE, 87108 Albuquerque, NM, USA. 6. Baylor College of Medicine, One Baylor Plaza, 77030 Houston, TX, USA; Michael E. DeBakey VA Medical Center, 2002 Holcombe Blvd, 77030 Houston, TX, USA. Electronic address: Reina.Villareal@bcm.edu.
Abstract
INTRODUCTION: Both hypogonadism and type 2 diabetes mellitus (T2D) are associated with increased fracture risk. Emerging data support the negative effect of low testosterone on glucose metabolism, however, there is little information on the bone health of hypogonadal men with diabetes. We evaluated the bone mineral density (BMD), bone geometry and bone turnover of hypogonadal men with T2D compared to hypogonadal men without diabetes. MATERIALS AND METHODS: Cross-sectional study, men 40-74years old, with average morning testosterone (done twice) of<300ng/dl. Areal BMD (aBMD) was measured by DXA; volumetric BMD (vBMD) and bone geometry by peripheral-quantitative-computed-tomography; serum C-telopeptide (CTX), osteocalcin, sclerostin and sex hormone-binding globulin (SHBG) by ELISA, testosterone and 25-hydroxyvitamin D (25OHD) by automated immunoassay and estradiol by liquid-chromatography/mass-spectrometry. Groups were compared by ANOVA adjusted for covariates. RESULTS: One-hundred five men, 49 with and 56 without diabetes were enrolled. Adjusted vBMD at 38% tibia was higher in diabetic than non-diabetic men (857.3±69.0mg/cm3 vs. 828.7±96.7mg/cm3, p=0.02). Endosteal (43.9±5.8mm vs. 47.1±7.8mm, p=0.04) and periosteal (78.4±5.0mm vs. 81.3±6.5mm, p=0.02) circumferences and total area (491.0±61.0mm2 vs. 527.7±87.2mm2, p=0.02) at 38% tibia, were lower in diabetic men even after adjustments for covariates. CTX (0.25±0.14ng/ml vs. 0.40±0.19ng/ml, p<0.001) and osteocalcin (4.8±2.8ng/ml vs. 6.8±3.5ng/ml, p=0.006) were lower in diabetic men; there were no differences in sclerostin and 25OHD. Circulating gonadal hormones were comparable between the groups. CONCLUSION: Among hypogonadal men, those with T2D have higher BMD, poorer bone geometry and relatively suppressed bone turnover. Studies with larger sample size are needed to verify our findings and possible even greater risk for fractures among hypogonadal diabetic men. Published by Elsevier Inc.
INTRODUCTION: Both hypogonadism and type 2 diabetes mellitus (T2D) are associated with increased fracture risk. Emerging data support the negative effect of low testosterone on glucose metabolism, however, there is little information on the bone health of hypogonadal men with diabetes. We evaluated the bone mineral density (BMD), bone geometry and bone turnover of hypogonadal men with T2D compared to hypogonadal men without diabetes. MATERIALS AND METHODS: Cross-sectional study, men 40-74years old, with average morning testosterone (done twice) of<300ng/dl. Areal BMD (aBMD) was measured by DXA; volumetric BMD (vBMD) and bone geometry by peripheral-quantitative-computed-tomography; serum C-telopeptide (CTX), osteocalcin, sclerostin and sex hormone-binding globulin (SHBG) by ELISA, testosterone and 25-hydroxyvitamin D (25OHD) by automated immunoassay and estradiol by liquid-chromatography/mass-spectrometry. Groups were compared by ANOVA adjusted for covariates. RESULTS: One-hundred five men, 49 with and 56 without diabetes were enrolled. Adjusted vBMD at 38% tibia was higher in diabetic than non-diabeticmen (857.3±69.0mg/cm3 vs. 828.7±96.7mg/cm3, p=0.02). Endosteal (43.9±5.8mm vs. 47.1±7.8mm, p=0.04) and periosteal (78.4±5.0mm vs. 81.3±6.5mm, p=0.02) circumferences and total area (491.0±61.0mm2 vs. 527.7±87.2mm2, p=0.02) at 38% tibia, were lower in diabeticmen even after adjustments for covariates. CTX (0.25±0.14ng/ml vs. 0.40±0.19ng/ml, p<0.001) and osteocalcin (4.8±2.8ng/ml vs. 6.8±3.5ng/ml, p=0.006) were lower in diabeticmen; there were no differences in sclerostin and 25OHD. Circulating gonadal hormones were comparable between the groups. CONCLUSION: Among hypogonadal men, those with T2D have higher BMD, poorer bone geometry and relatively suppressed bone turnover. Studies with larger sample size are needed to verify our findings and possible even greater risk for fractures among hypogonadal diabeticmen. Published by Elsevier Inc.
Entities:
Keywords:
Bone; Bone geometry; Hypogonadism; T2D; Testosterone
Authors: Joshua N Farr; Matthew T Drake; Shreyasee Amin; L Joseph Melton; Louise K McCready; Sundeep Khosla Journal: J Bone Miner Res Date: 2014-04 Impact factor: 6.741
Authors: Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2010-06 Impact factor: 5.958
Authors: J S Manavalan; S Cremers; D W Dempster; H Zhou; E Dworakowski; A Kode; S Kousteni; M R Rubin Journal: J Clin Endocrinol Metab Date: 2012-06-27 Impact factor: 5.958
Authors: Nicola Napoli; Elsa S Strotmeyer; Kristine E Ensrud; Deborah E Sellmeyer; Douglas C Bauer; Andrew R Hoffman; Thuy-Tien L Dam; Elizabeth Barrett-Connor; Lisa Palermo; Eric S Orwoll; Steven R Cummings; Dennis M Black; Ann V Schwartz Journal: Diabetologia Date: 2014-06-09 Impact factor: 10.122
Authors: Sandeep Dhindsa; Michael G Miller; Cecilia L McWhirter; Donald E Mager; Husam Ghanim; Ajay Chaudhuri; Paresh Dandona Journal: Diabetes Care Date: 2010-03-03 Impact factor: 19.112
Authors: Nicola Napoli; Ann V Schwartz; Lisa Palermo; Jenny J Jin; Rosanna Wustrack; Jane A Cauley; Kristine E Ensrud; Michael Kelly; Dennis M Black Journal: J Clin Endocrinol Metab Date: 2013-01-23 Impact factor: 5.958
Authors: Nicola Napoli; Manju Chandran; Dominique D Pierroz; Bo Abrahamsen; Ann V Schwartz; Serge L Ferrari Journal: Nat Rev Endocrinol Date: 2016-09-23 Impact factor: 43.330
Authors: Elliot Ballato; F N U Deepika; Vittoria Russo; Alcibiades Fleires-Gutiérrez; Georgia Colleluori; Virginia Fuenmayor; Rui Chen; Dennis T Villareal; Clifford Qualls; Reina Armamento-Villareal Journal: Calcif Tissue Int Date: 2022-06-04 Impact factor: 4.000